- Home
- SCHL vs LRMR Comparison
SCHL vs LRMR Comparison
Compare SCHL & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCHL
- LRMR
- Stock Information
- Founded
- SCHL 1920
- LRMR N/A
- Country
- SCHL United States
- LRMR United States
- Employees
- SCHL N/A
- LRMR N/A
- Industry
- SCHL Books
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- SCHL Consumer Discretionary
- LRMR Health Care
- Exchange
- SCHL Nasdaq
- LRMR Nasdaq
- Market Cap
- SCHL 501.9M
- LRMR 426.9M
- IPO Year
- SCHL 1987
- LRMR N/A
- Fundamental
- Price
- SCHL $20.60
- LRMR $3.19
- Analyst Decision
- SCHL
- LRMR Strong Buy
- Analyst Count
- SCHL 0
- LRMR 9
- Target Price
- SCHL N/A
- LRMR $19.44
- AVG Volume (30 Days)
- SCHL 313.8K
- LRMR 630.8K
- Earning Date
- SCHL 03-20-2025
- LRMR 03-13-2025
- Dividend Yield
- SCHL 3.93%
- LRMR N/A
- EPS Growth
- SCHL N/A
- LRMR N/A
- EPS
- SCHL N/A
- LRMR N/A
- Revenue
- SCHL $1,580,400,000.00
- LRMR N/A
- Revenue This Year
- SCHL $5.93
- LRMR N/A
- Revenue Next Year
- SCHL $5.29
- LRMR N/A
- P/E Ratio
- SCHL N/A
- LRMR N/A
- Revenue Growth
- SCHL N/A
- LRMR N/A
- 52 Week Low
- SCHL $17.72
- LRMR $3.01
- 52 Week High
- SCHL $40.71
- LRMR $12.91
- Technical
- Relative Strength Index (RSI)
- SCHL 53.59
- LRMR 37.56
- Support Level
- SCHL $19.35
- LRMR $3.06
- Resistance Level
- SCHL $21.26
- LRMR $3.52
- Average True Range (ATR)
- SCHL 0.77
- LRMR 0.22
- MACD
- SCHL 0.26
- LRMR 0.02
- Stochastic Oscillator
- SCHL 81.36
- LRMR 15.66
About SCHL Scholastic Corporation
Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.